K-Nor Powder
Calcium polystyrene sulfonate (Calcium Resonium)
300 gm/300 gm
Popular Pharmaceuticals Ltd.
| Pack size | |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 980.00 AED |
Indications
K-Nor Powder is used for:
Hyperkalemia, due to acute & chronic renal failure.
Adult Dose
Oral
Adult
The intensity and duration of therapy depend upon the severity and resistance of hyperkalemia.
15-60 g daily orally, suspended in 30-50 mL water, in 3-4 divided doses.
Child Dose
Oral
Children
½ adult dose.
An appropriate initial dose is 1g/kg body weight daily in divided doses, in acute hyperkalaemia.
Dosage may be reduced to 0.5g/kg body weight daily in divided doses for maintenance therapy.
Renal Dose
Administration
Should be taken on an empty stomach.
Oral Preparation
For each gram of powdered resin add 3-4 mL of water or syrup
Do not heat the solution to improve dissolution; heat impairs resin exchange
Oral Administration
Shake the suspension well before administering
Administer PO or via NG tube with the patient in the upright position
Do not take other oral medications within 3 hr of dosing (6 hr for patients with gastroparesis or other conditions) because of potential GI binding
Do not mix with potassium-containing liquids or food (eg, orange juice, bananas)
Suspension may be chilled to improve palatability
Contra Indications
Hypersensitivity to polystyrene sulfonate resins.
Hyperparathyroidism, multiple myeloma, sarcoidosis or carcinoma metastases w/ renal failure & hypercalcemia.
Serum K level <5 mmol/L.
Precautions
Intestinal Necrosis: cases of intestinal necrosis and other serious gastrointestinal events have been reported (5.1).
Electrolyte Disturbances: Severe hypokalemia can occur. (5.2).
Fluid overload in patients sensitive to high sodium intake: Monitor patients who are sensitive to sodium intake for signs of fluid overload.
Risk of aspiration: Acute bronchitis or bronchopneumonia caused by inhalation of sodium polystyrene sulfonate particles has been reported.
Discontinue use as soon as serum K level falls to 5 mmol/L; clinically significant constipation.
Mg-containing laxatives should not be used. Aspiration.
Concomitant use w/ sorbitol.
MONITORING PARAMETERS
Monitor serum potassium frequently within each 24 hr period.
Monitor for electrolyte disturbances (stop if plasma-potassium concentration is below 5 mmol/liter).
Monitor patients who are sensitive to sodium intake for signs of fluid overload.
ECG monitoring may be appropriate in some patients.
Regularly monitor serum Mg, Ca & K levels.
Pregnancy-Lactation
Pregnancy
Not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk
Lactation
Not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant
Interactions
Take other orally administered drugs at least 3 hours before or 3 hours after Calcium polystyrene sulfonate.
Cation-donating antacids: may reduce the resin’s potassium exchange capability and increase the risk of systemic alkalosis.
Sorbitol: Concomitant use may contribute to the risk of intestinal necrosis and is not recommended.
Depletion of serum K level may increase digitalis intoxication.
Cation-donating agents may reduce effectiveness in binding K.
Intestinal obstruction w/ Al hydroxide.
The toxic effects of digoxin may be exaggerated if hypokalemia &/or hypercalcemia develop.
Contraindicated (1)
meloxicam
Serious (1)
sorbitol
Adverse Effects
Side effects of Calcium polystyrene sulfonate (Calcium Resonium) :
1-10%
GI disturbance
Constipation
Hypokalemia
Hypocalcemia
Hypomagnesemia
Sodium retention
Nausea
Vomiting
Frequency Not Defined
GI concretions (bezoars) after oral use
GI tract ulceration or necrosis, which could lead to perforation
Fecal impaction after rectal administration (especially in children)
Acute bronchitis or bronchopneumonia associated with inhalation of polystyrene particles (rare)
Mechanism of Action
Calcium Polystyrene Sulfonate acts by a cumulative process throughout the gastrointestinal tract, removing potassium ions which are excreted in the feces. Calcium Polystyrene Sulfonate passes through the colon and comes into contact with fluids containing increased amounts of potassium. The result is that potassium is taken up in increasing amounts in exchange for calcium ions.
The length of time Calcium Polystyrene Sulfonate remains in the body is a decisive factor in its effectiveness. For this reason oral administration is more effective than rectal administration
Note
K-Nor 300 gm/300 gm Powder manufactured by Popular Pharmaceuticals Ltd.. Its generic name is Calcium polystyrene sulfonate (Calcium Resonium). K-Nor is availble in Bangladesh.
Farmaco BD drug index information on K-Nor Powder is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.